Vaccine Tested to Protect Against Mosquito-Borne Diseases

February 21, 2017

(UPI) – Researchers from the National Institutes of Health, or NIH, are testing a new vaccine designed to target mosquito saliva to protect against mosquito-borne diseases. The National Institute of Allergy and Infectious Diseases, or NIAID, part of the NIH, has launched a Phase 1 clinical trial of a new vaccine that could provide widespread protection against a variety of mosquito-borne diseases like Zika, malaria, West Nile virus and dengue fever.